心不全におけるアンジオテンシン変換酵素阻害剤とアンジオテンシンII受容体ブロッカーの併用療法の理論的根拠

文献

J-GLOBAL ID：200902267876674465 整理番号：04A0249298

Rationale for the Use of Combination Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Therapy in Heart Failure

出版者サイト {{ this.onShowPLink() }} 複写サービスで全文入手
高度な検索・分析はJDreamⅢで {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=04A0249298&from=J-GLOBAL&jstjournalNo=F0908A") }}

著者 (9件)： , , , , , , , ,
資料名：
巻： 68 号： 4 ページ： 361-366 発行年： 2004年04月
JST資料番号： F0908A ISSN： 1346-9843 資料種別：逐次刊行物 (A)
記事区分：原著論文発行国：日本 (JPN) 言語：英語 (EN)

左心室リモデリングの抑制および神経体液性因子阻害に対するアン...

,...
,...

続きはJDreamIII（有料）にて {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=04A0249298&from=J-GLOBAL&jstjournalNo=F0908A") }}

循環系疾患の薬物療法

引用文献 (11件)：

1. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN for the Vasodilator Heart Failure Trial (V-HeFT) Study Group. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999; 99: 2658-2664.
2. Carson PE. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. Am Heart J 2000; 140: 361-366.
3. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al for RESOLVD Pilot Study Investigators. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999; 100: 1056-1064.
4. Cohn JN, Tognori G for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
5. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003; 362: 767-771.

, , , , , , ,

前のページに戻る